Press Releases
NeOnc Technologies Holdings is committed to providing the latest information on its patented and novel drug-delivery technology platform. The following offers media and healthcare professionals important press releases related to the company’s progress.
NeOnc Begins Enrollment for Phase 2 Clinical Trial of NEO100-02
NeOnc has begun its Phase 2 Clinical Trials to study the safety and preliminary evidence of the biological effects of its NEO100 formulation.
NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212
NeOnc has begun enrollment of patients for Cohort 3 out of 6 of the Phase 1 clinical trial of its NEO212™ formulation for treating tumor-based brain cancer.
NeOnc Technologies Completes $18.5 Million Financing
$18.5 million financing advances Phase II Clinical Trials for delivering novel therapeutics to the Brain under FDA Fast-Track status.
NeOnc Receives Breakthrough Medical Technology Achievement Award from CIS
The California Investment Forum recognizes NeOnc Technologies for its innovations in medical technology related to the treatment of brain and central nervous system diseases.
NeOnc’s CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’
NeOnc announced that its CEO, Thomas Chen, MD, Ph.D., has received the Best in Medicine Award from the American Health Council (AHC).
NeOnc Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100®
NeOnc has expanded its engagement of Anova Enterprises to pursue a pediatric indication for NEO100 for patients with Pediatric High-Grade Gliomas (pHGGS) brain tumors.